Taiwan FDA registration 8425af22ebdaea18d05971ebe3b93faa

Firstep MET/MDMA Drug Screen Rapid Test

TW: 聯華甲基安非他命/搖頭丸藥物濫用篩檢測試組

Taiwan·Risk Class 2·MD·FIRSTEP BIORESEARCH INC.·Registered Feb 24, 2017 – Feb 24, 2027Active

Registration details

Analysis ID: 8425af22ebdaea18d05971ebe3b93faa
License Form: Ministry of Health Medical Device Manufacturing No. 005597

Company information

Manufacturer: FIRSTEP BIORESEARCH INC.
Manufacturer Country: Taiwan, Province of China
Authorized Representative: FIRSTEP BIORESEARCH INC.

Product details

Intended Use: This product uses immunoqualitative analysis methods to test methamphetamine/ecstasy and its metabolites in human urine. The detection threshold for this product is 500 ng/mL. Performance Change: This product uses immunoqualitative analysis methods to test for methamphetamine/ecstasy and its metabolites in human urine. This product can be used by professionals and the general public. The detection threshold for this product is 500 ng/mL.
Product Type (Level 1): A Clinical chemistry and clinical toxicology
Product Type (Level 2): A3610 Methamphetamine Test System
Import Information: Produced in Taiwan, China

Dates and status

Registration Date: Feb 24, 2017
Expiry Date: Feb 24, 2027

About this record

Access comprehensive regulatory information for Firstep MET/MDMA Drug Screen Rapid Test in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 8425af22ebdaea18d05971ebe3b93faa and manufactured by FIRSTEP BIORESEARCH INC.. The authorized representative in Taiwan is FIRSTEP BIORESEARCH INC..

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.